Related Experiment Videos
Pharmacogenomics and functional gastrointestinal disorders
1Mayo Clinic College of Medicine, Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Gastroenterology Research Unit, Charlton 8-110200 First Street S.W., Rochester, MN 55905, USA.
Pharmacogenomics
|July 15, 2005
Summary
Pharmacogenomics can improve the safety and efficacy of medications for functional gastrointestinal disorders like irritable bowel syndrome. Genetic variations influence drug metabolism and treatment response, paving the way for personalized gastroenterology pharmacotherapeutics.
Area of Science:
- Gastroenterology
- Pharmacogenomics
- Internal Medicine
Background:
- Functional gastrointestinal disorders (FGIDs), such as irritable bowel syndrome and functional dyspepsia, are highly prevalent, affecting roughly 25% of individuals in Western societies.
- Current management strategies for FGIDs often involve medications with variable efficacy and safety profiles.
- The need for personalized treatment approaches in FGID management is increasingly recognized.
Purpose of the Study:
- To review the role of pharmacogenomics in optimizing the safety and efficacy of medications used for FGIDs.
- To highlight specific examples of how genetic variations impact drug response in gastroenterology.
- To discuss the potential of pharmacogenomics to revolutionize pharmacotherapeutics in digestive health.
Main Methods:
- Literature review of studies examining pharmacogenomic applications in FGID pharmacotherapy.
- Analysis of examples involving cytochrome P450 enzyme polymorphisms (e.g., CYP2D6, CYP2C19) and their effect on drug metabolism.
- Examination of genetic polymorphisms in the serotonin transporter gene (e.g., 5-HTTLPR) and their influence on treatment outcomes, specifically with alosetron.
Main Results:
- Genetic variations in cytochrome P450 enzymes significantly affect the metabolism and efficacy of various FGID medications.
- Polymorphisms in the serotonin transporter gene promoter influence patient response to drugs like alosetron, particularly in diarrhea-predominant irritable bowel syndrome.
- Pharmacogenomic insights offer a basis for predicting drug response and tailoring treatment for individual patients with FGIDs.
Conclusions:
- Pharmacogenomics holds significant promise for enhancing the precision and effectiveness of pharmacotherapy in gastroenterology.
- Personalized medicine approaches, guided by genetic information, are expected to improve patient outcomes for functional gastrointestinal disorders.
- The integration of pharmacogenomics into clinical practice represents a paradigm shift towards a new era in gastrointestinal pharmacotherapeutics.